<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11414">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01672606</url>
  </required_header>
  <id_info>
    <org_study_id>OSA ROC</org_study_id>
    <nct_id>NCT01672606</nct_id>
  </id_info>
  <brief_title>Effect of Rocuronium on the Acute Hypoxic Ventilatory Response in Patients With Obstructive Sleep Apnea</brief_title>
  <official_title>Effect of Partial Neuromuscular Blockade by Rocuronium on the Acute Hypoxic Ventilatory Response in Patients With Obstructive Sleep Apnea-before and After Three Month CPAP Treatment. A Non-randomized, Non-blinded Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Malin Jonsson Fagerlund</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <authority>Sweden: Medical Products Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study describe the effect of partial neuromuscular blockade of rocuronium on the acute
      hypoxic ventilatory response in patients with OSA before and after 3 month of CPAP
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Hypoxic ventilatory response</measure>
    <time_frame>At baseline, with CPAP, at TOF 0.70 and at TOF &gt;0.90. At diagnosis and after 3 month of CPAP treatment at home</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypercarbic ventilatory response</measure>
    <time_frame>At baseline, with CPAP, at TOF 0.70 and at TOF &gt;0.90. At diagnosis and after 3 month of CPAP treatment at home</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoxic ventilatory response</measure>
    <time_frame>At diagnosis and after 3 month of CPAP treatment at home</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoxic ventilatory response during acute CPAP treatment</measure>
    <time_frame>At diagnosis and after 3 month of CPAP treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypercarbic ventilatory response</measure>
    <time_frame>At diagnosis and after 3 month of CPAP treatment at home</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypercarbic ventilatory response during acute CPAP treatment</measure>
    <time_frame>At diagnosis and after 3 month CPAP treatment at home</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Upper airway obstruction</measure>
    <time_frame>At TOF 0.70 and TOF &gt;0.90. At diagnosis and after 3 month CPAP treatment.</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>OSA</condition>
  <condition>Rocuronium</condition>
  <condition>Neuromuscular Blockade</condition>
  <condition>Hypoxic Ventilatory Response</condition>
  <condition>CPAP</condition>
  <arm_group>
    <arm_group_label>Rocuronium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of rocuronium with the goal of TOF 0.70 and &gt;0.90</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium</intervention_name>
    <description>Partial neuromuscular blockade with rocuronium with a TOF 0.70</description>
    <arm_group_label>Rocuronium</arm_group_label>
    <other_name>CPAP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male with diagnosed moderate OSA (AHI 15-30), untreated, but planned for CPAP
             treatment. Healthy except for OSA and well controlled tablet treated hypertension
             where the treatment has not been changed during the last 3 month. None smokers. 18-70
             years old. BMI &lt;35.

        Exclusion Criteria:

          -  If they donÂ´t fit the inclusion criteria
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malin Jonsson Fagerlund, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital and Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anesthesiology, Surgical Sciences and Intensive Care Medicine, Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>se-17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>June 1, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Malin Jonsson Fagerlund</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
